In recent years, exosomes have gained attention as a strategy for accessing the therapeutic effects of cells without the risks and difficulties of administering the cells to patients. With at least 22,143 scientific articles published about exosomes and 253 clinical trials underway, these small vesicles have intriguing potential to be used within a

Thanks to Nurexone’s performance in recent weeks on the TSXV compared to the market, it has received the badge – shows up on NurExone’s page on the TMX website – and it is now listed on the top healthcare page. Read More …

NurExone Biologic‘s team members Dr. Lior Shaltiel, PhD and Inbar Paz Benayoun, Adv. will attend The OTC Markets Group OTCQX Annual Issuer’s Forum in London. Another great opportunity to expand business strategies, synergies and developments with partners and colleagues!   Read More …

We are pleased to introduce NurExone Biologic‘s talented team members, each star at a time..! This time it’s our very own Dr. Irit Dolgopyat, PhD, R&D scientist at NurExone! Check out Irit’s interview about her role and work environment: 1. What R&D scientist do? Designing experiments that systematically characterize and improve the

With its technology showing promising results for spinal cord injuries, NurExone Biologic is making significant progress toward becoming a market leader in exosome-based treatment. Read our industry update below. Read More …

The demand for spinal cord injury (SCI) treatment has increased significantly because of the growing incidence of traumatic spinal cord injuries. According to a 2018 report from the United States National Library of Medicine, the prevalence of traumatic spinal cord injuries in low and middle-income countries was 8.72% per 100,000 people,

With its technology showing promising results for spinal cord injuries, NurExone Biologic is making significant progress toward becoming a market leader in exosome-based treatment. Read our industry update below. The demand for spinal cord injury (SCI) treatment has increased significantly because of the growing incidence of traumatic spinal cord injuries.

This time it’s our very own Dr. Irit Dolgopyat, PhD, R&D scientist at NurExone! Check out Irit’s interview about her role and work environment: 1. What R&D scientist do? Designing experiments that systematically characterize and improve the product. This role engages a great deal of strategic planning and creative problem solving.

A biopharmaceutical company based in Israel is moving closer to revolutionizing the treatment of spinal cord injuries for U.S. patients through regenerative medicine. NurExone Biologic Inc., Ltd., which completed a reverse takeover (RTO) in June 2022 (TSXV: NRX) (FSE: J90), is developing a biotech platform called ExoTherapy. The company will

“The only thing in our hands is to make a company public. When it’s public, everything is transparent, people can invest and that will drive innovation” – Lior Shaltiel, PhD   Read More….